GlassScriptPhysician profile
Calvin K Lee
NPI 1003117136
$4,729.95
in general payments reported to CMS, 2019-2025
14 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $1,024 · 2023: $609 · 2024: $819 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,059.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,591.01 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $961.80 | 2022-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $815.18 | 2024-2025 | Rezdiffra |
| Intra-Sana Laboratories | $392.53 | 2022-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ipsen Biopharmaceuticals, INC | $356.83 | 2023-2025 | Bylvay, Iqirvo |
| Abbvie INC. | $207.82 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $201.84 | 2023-2025 | Terlivaz |
| Boston Scientific Corporation | $60.95 | 2024 | Spyglass, Spyglass Discover |
| Invivyd INC | $32.69 | 2025 | Pemgarda |
| Mirum Pharmaceuticals, INC. | $31.85 | 2024-2025 | Livmarli, Chenodal, Cholbam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.37 | 2025 | Jardiance |
| Intercept Pharmaceuticals, INC. | $21.84 | 2022 | |
| Orphalan INC | $19.08 | 2024 | Cuvrior |
| Astrazeneca Pharmaceuticals LP | $14.16 | 2025 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.